NASDAQ · Biotechnology

ImmunityBio, Inc. (IBRX) Stock

$7.00 -1.48% NASDAQ: IBRX Healthcare

ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California.

Valuation

MetricValue
Price$7.00
Market Cap$7.33B
P/E Ratio-8.32
P/B Ratio-8.38
P/S Ratio52.75
EPS (TTM)$-0.85
52-Week High$12.43
52-Week Low$1.95
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE138.69%
ROA-132.15%
ROCE-45.17%
Gross Margin99.34%
Operating Margin-1.58%
Net Margin-606.15%
Debt/Equity-1.29
Current Ratio6.67

Annual Financials (USD)

Metric20212022202320242025
Revenue$1.0M$0$1.0M$15.0M$113.0M
Operating Profit$-330.0M$-351.0M$-362.0M$-344.0M$-256.0M
Net Profit$-347.0M$-417.0M$-583.0M$-414.0M$-351.0M
EPS$-0.89$-1.04$-1.15$-0.62$-0.38
Op Margin-35361.9%-146374.2%-58239.6%-2334.2%-226.0%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$469.0M$362.0M$504.0M$383.0M$502.0M
Total Liabilities$713.0M$812.0M$1.1B$871.0M$1.0B
Cash$181.0M$105.0M$265.0M$143.0M$88.0M
Borrowings$646.0M$724.0M$727.0M$504.0M$878.0M

Latest News

IBRX Stock Climbs Premarket Despite Investor Stake Cut — Retail Sees ‘Imminent’ Global Rollout Catalyst Stocktwits · Jul 14, 2026 Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout 24/7 Wall St. · Jul 10, 2026 Can IBRX Stock Keep Its Pulse? Institutional Investors Buy In, Retail Hopes For Big Q2 Surprise Stocktwits · Jul 10, 2026 ImmunityBio Insider Sold Shares Worth $1,246,941, According to a Recent SEC Filing MT Newswires · Jul 7, 2026 ImmunityBio Insider Sold Shares Worth $1,439,066, According to a Recent SEC Filing MT Newswires · Jul 7, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-274.0M$-338.0M$-367.0M$-391.0M$-305.0M
Investing Cash Flow$-118.0M$-51.0M$-61.0M$-19.0M$-154.0M
Financing Cash Flow$167.0M$60.0M$190.0M$73.0M$-2.0M
Net Cash Flow$146.0M$-76.0M$161.0M$-122.0M$-54.0M
Free Cash Flow$-308.0M$-416.0M$-397.0M$-398.0M$-309.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.55
EV / EBITDA-11.35
FCF Yield-4.22%
Quick Ratio6.24
Interest Coverage-2.27
Return 1Y201.12%
Return 3Y187.19%
Return 5Y-27.69%

Ownership

Insiders Held62.47%
Institutions Held17.66%
Institutions Float Held47.05%
Institutional HolderSharesReport Date
Blackrock Inc.26,346,4432026-03-31
State Street Corporation17,708,1032026-03-31
Vanguard Portfolio Management LLC16,322,8442026-03-31
Vanguard Capital Management LLC15,127,7142026-03-31
Shaw D.E. & Co., Inc.12,571,5972026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About ImmunityBio, Inc.

ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.

ImmunityBio, Inc. is led by CEO Richard Gerald Adcock, employs 691 people, headquartered in San Diego, US, publicly traded since 2015.

ImmunityBio, Inc. (IBRX) stock trades at $7.00 with a market capitalization of $7.33B. The stock is valued at a price-to-earnings (P/E) ratio of -8.32, price-to-book of -8.38, price-to-sales of 52.75. Over the past 52 weeks the stock has ranged between $1.95 and $12.43, and currently trades 43.7% below its 52-week high.

On profitability, ImmunityBio, Inc. generates a return on equity (ROE) of 138.69% — well above the market average, a sign of a high-quality business, return on capital employed of -45.17%, an operating margin of -1.58%, a net profit margin of -606.15%.

Official website: immunitybio.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides